Ignite Creation Date:
2025-12-17 @ 4:23 PM
Ignite Modification Date:
2025-12-24 @ 1:02 AM
Study NCT ID:
NCT00724958
Status:
COMPLETED
Last Update Posted:
2015-10-02
First Post:
2008-07-25
Is Possible Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Study Overview
Official Title:
Real Life Dosing Regimen of Remicade in Austria in Crohn's Disease - Program Extension
Status:
COMPLETED
Status Verified Date:
2015-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The current observational program was determined to collect data on the real life dosing regimen of Remicade in patients with Crohn's disease (CD) in the hospital and non-hospital setting.
Detailed Description:
This study population was chosen from a non-probability sample
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: